Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Pilot Feasibility Trial

NCT07579195 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07579195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07579195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Pilot Feasibility Trial
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 20, 2026
Completion date
February 1, 2030
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder carcinoma, stage iii bladder cancer ajcc v8, stage iv bladder cancer ajcc v8